United States: FDA Comes Through On Promise To Release NGS Device Draft Guidelines Expeditiously

Building on last year's public workshops related to Next-Generation Sequencing (NGS) and expanding its efforts to advance the Obama Administration's Precision Medicine Initiative, the FDA late last week released two draft guidance documents on different aspects of NGS-based diagnostic tests. NGS is a term used to describe new technologies that allow rapid sequencing of large segments of an individual's DNA or entire genomes, as we have described previously. The Agency's stated goal is "to create a flexible and adaptive regulatory approach to the oversight of NGS-based tests," given the rapid and innovative advancements being made in the technologies.

The significance of this move by the Agency also is highlighted by the fact that a press release was issued to announce it, something that is typically not done for more "routine" guidance documents that come out of one or more of the FDA Centers on an almost daily basis. An earlier draft guidance on the use of NGS for infectious disease applications (released in May with an August 11 deadline for comments) did not receive nearly as much fanfare as these two new proposed guidelines.

Of the two new policies, the first draft guidance describes an approach to allow test developers to rely on clinical evidence from FDA-recognized public genome databases to support claims for their tests and to provide assurance of accurate clinical interpretation of genomic test results, potentially offering a streamlined path to approval. The second document provides recommendations for designing, developing, and validating NGS-based tests for rare hereditary diseases and addresses the potential for using FDA-recognized standards to show analytical validity.

Use of Public Databases to Support Clinical Validity of NGS-Based Tests

The first draft guidance document, entitled "Use of Public Human Genetic Varian Databases to Support Clinical Validity for NGS-Based In Vitro Diagnostics," sets forth how the Agency views the data and so-called assertions contained within a genetic variant database. An "assertion" is an informed assessment by qualified personnel about a genotype-phenotype correlation given the current state of knowledge for a particular variant. The key takeaways from this proposed approach by FDA are:

  • Well-recognized professional guidelines for making assertions generally are expected to meet existing regulatory requirements for "valid scientific evidence" to support the analytical and clinical performance, and by extension the safety and effectiveness, of a device (in this case an in vitro diagnostic device or IVD).
  • In order to serve this role as "valid scientific evidence" to support an NGS-based test, a curated database of human genetic variants must meet certain features intended to ensure high-quality procedures and data sets.
  • Those Agency recommendations are that a given database should "(1) operate in a manner that provides sufficient information and assurances regarding the quality of source data and its evidence review and variant assertions; (2) provide transparency regarding its data sources and its operations, particularly how variant evidence is evaluated and interpreted; (3) collect, store, and report data and conclusions in compliance with all applicable requirements regarding protected health information, patient privacy, research subject protections, and data security; and (4) house sequence information generated by validated methods."
  • If a genetic variant database meets those quality requirements, as further fleshed out in FDA's draft document, the Agency states that the database administrators could then request (voluntarily, of course) recognition from the Agency that the assertions contained within it be considered "valid scientific evidence" to support a future NGS-test premarketing review submission. The developer of an NGS-based test would then incorporate the recognized database's assertions about specific genetic variants and the data supporting those assertions in its submission. FDA's proposed Recognition Process for Genetic Variant Databases would, most critically, include a review of the policies, procedures, and other documentation from the database; such information would be expected to be made public by the database administrator after receiving FDA recognition as part of the transparency commitment.

FDA's goal in allowing developers of NGS-based tests to rely on assertions in carefully curated genetic databases is simultaneously to "encourage the deposition of variant information in such databases, reduce regulatory burden on test developers, and spur advancements in the interpretation and implementation of precision medicine."

Use of Standards in FDA Oversight of NGS Tests for Germline Disease Diagnosis

"Use of Standards in FDA Regulatory Oversight of NGS-Based In Vitro Diagnostics Used for Diagnosing Certain Germline Diseases" is the name of the second draft guidance just issued by the Agency. The document provides recommendations to developers of NGS-based tests regarding the design, development, and validation of such tests for germline diseases only – that is, genetic diseases or other conditions are inherited or de novo mutations in egg or sperm cells (i.e., not mutations that arise from DNA damage after birth through exposure to environmental contaminants or as a result of other factors). It also does not apply to other types of NGS-based tests, such as fetal testing or tumor genome sequencing, among other applications of NGS expressly excluded from this proposed policy by the Agency. Accordingly, therefore, this initial foray by FDA into providing regulatory advice to NGS stakeholders is narrowly limited to a subset of the massive potential for the application of NGS-based technologies.

In addition, the key takeaways from this FDA proposed policy are:

  • An NGS-based test for germline disease may be appropriate for classification as a Class II device, through the de novo classification process, because "there is a reasonable probability that the risks associated with [such tests] (e.g., those related to the consequences of a false positive or negative result provide to a patient) may be sufficiently mitigated by a combination of general and special controls, and that the safety and effectiveness of this type of test may be reasonably assured by such controls." This discussion is practically an invitation by the Agency for someone, anyone, to submit a de novo classification request for NGS-based tests with this specific intended use.
  • Once classification is established, even if as a Class II device, it is possible that FDA may exempt the NGS-based test for germline disease from premarket notification requirements of section 510(k) of the FD&C Act. Importantly, FDA would not alter any "limitations of exemption," meaning that, according to prior guidance and regulation, the 510(k) exemption would be exceeded if there is a different intended use or technology. Exemption from the premarket notification requirements may be established based on conformance with FDA-recognized standards for analytical validity, although the guidance notes "FDA has not yet determined how conformity with standards...should be demonstrated and plans to discuss this in future guidance documents."
  • The remainder of the guidance delves into detailed recommendations for design, development, and validation of NGS-based tests for germline diseases. The detail reads much like other product specific guidances describing the content of premarket submissions. Initially, the guidance characterizes NGS-based tests for germline diseases so a test developer will be able to determine if their test is, in fact, captured by the guidance. If so, then specifics for indications for use, accuracy and performance, and test validation are described in detail.
  • Content and format of Test Reports for the end users (health care professionals or consumers) are summarized, with requirements for such reports to include information about test limitations and information about any unknown variants.

Perhaps what is most telling in the draft guidance documents is what is missing or what is specifically carved out. Neither addresses how these policies will intersect with FDA plans for LDTs, and although we previously described FDA's plans for a final LDT policy in early 2016, nothing has been finalized to date. Certainly there will be an intersection because the FDA policy set forth in these two guidance documents specifically focuses on the recommendations for preparing a premarket submission, leaving open the specific question of when enforcement discretion will be exercised, if at all, for NGS-based tests. The second guidance addressing "Use of Standards" importantly notes that while FDA is willing to recognize scientific standards, "FDA is unaware of any existing, comprehensive standard for analytical validation applicable to NGS-based tests for germline diseases that it believes could be used to help provide reasonable assurance of the safety and effectiveness of these tests." Maybe the title will be reconsidered before finalization of the guidance.

We will be posting further analysis and commentary on these proposed policies, and we plan to provide recommendations to potentially affected stakeholders who may want to submit their feedback to FDA. Public comments on these two NGS draft guidances are being accepted until October 6, 2016. A list of specific questions from the Agency to interested parties about the policies and regulatory approaches laid out in each document can be viewed in the July 8 Federal Register notices of availability – available here for "Use of Databases" and here for "Use of Standards."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions